Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts

This is the first case of decitabine plus lenalidomide treatment for a myelodysplastic syndrome (MDS) patient with 5q deletion (del(5q)) and elevated number of blasts. Upon bone marrow aspiration and biopsy with conventional cytogenetical studies she was diagnosed with MDS with del(5q) and refractor...

Descripción completa

Detalles Bibliográficos
Autores principales: Serin, Istemi, Eren, Rafet, Dogu, Mehmet Hilmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188382/
https://www.ncbi.nlm.nih.gov/pubmed/32362984
http://dx.doi.org/10.14740/jh618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188382/
https://www.ncbi.nlm.nih.gov/pubmed/32362984
http://dx.doi.org/10.14740/jh618

Ejemplares similares